Healthcare Industry News: Alzheimer’s disease
News Release - January 10, 2011
Neuroptix Closes C Round FinancingPioneer in non-invasive eye test for Alzheimer’s raises additional VC funding to accelerate clinical development
ACTON, Mass.--(Healthcare Sales & Marketing Network)-- Neuroptix Corporation, a leading innovator in the early detection of Alzheimer’s disease through a non-invasive eye test, today announced that it has closed the first approximately $4 Million tranche of a Series C funding round, as the company continues clinical development of its diagnostic platform.
The investment is led by Inventages, and will be funded in two tranches totalling approximately $8 Million, contingent on the successful completion of milestones. The Neuroptix SAPPHIRE II System is a combination product, consisting of an optical measurement device and topical ophthalmic agent being developed to aid in the diagnosis of probable Alzheimer’s disease.
Gunnar Weikert, Chairman, CEO and Founder of Inventages, said, “Neuroptix is addressing a critical need for a cost-effective diagnostic solution which may be administered at point-of-care. Alzheimer’s disease is a huge and growing problem which can only be addressed through a combination of early diagnosis and therapy.”
Paul Hartung, President and CEO of Neuroptix, said, “Neuroptix has made great strides in the development of our innovative product. The same proteins that form plaque in the brain grow in the lens of the eye, which provides a wonderful opportunity for a non-invasive test. This financing provides us with resources to move our SAPPHIRE II product through clinical studies. We are striving to help doctors identify Alzheimer’s disease in its earliest stages, where intervention will do the most good.”
About Neuroptix Corporation
Neuroptix is creating and developing an innovative, non-invasive eye test to assist in the early diagnosis of Alzheimer’s disease. Neuroptix’s goal is to provide clinicians with a quick, predictive, reliable, inexpensive and widely available test, enabling early diagnosis and treatment. The company maintains an active interest in collaboration with major pharmaceutical companies to facilitate testing of new Alzheimer’s drugs, and with academic institutions to promote research in this area.
For more information, please visit our website at www.neuroptix.com.
Inventages is one of the world's largest life-sciences, nutrition and wellness focused venture capital funds, with the resources to provide continued support to growing companies.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.